Welcome to Monaghan Medical Corporation
Science Based,
Outcome Driven
Let Breathing
Take Control
The AEROECLIPSE® II BAN™ Nebulizer creates aerosol only in response to the patient’s inspiratory flow.
Not All Chambers
Are Equal
Some “antistatic” valved holding chambers are only poorly antistatic and are noninterchangeable, which means that switching between them should be discouraged.¹
Clinically Supported to Improve
Patient Outcomes
Recent publications support use of the AEROBIKA® Oscillating Positive Expiratory Pressure device to help reduce readmissions or improve aerosol deposition when used alongside standard of care. 2
Recent Poster Presentations
Failure of Mycobacterium avium to Adhere to Interior Surfaces of Oscillating Positive Expiratory Pressure (OPEP) and Nebulizer Devices
Risk of respiratory infection is a common concern for bronchiectasis patients often leading to caution involving use of medical devices for inhalation. M. avium is a major cause of lung infection in bronchiectasis patients and is common in household drinking water that could be used to rinse respiratory devices.
Comparing Breath Actuated and Breath Enhanced Jet Nebulizers for the Delivery of Tobramycin
Nebulization is the mainstay of care for patients requiring inhaled antibiotic therapy in association with pulmonary diseases such as cystic fibrosis (CF), bronchiectasis and chronic obstructive lung disease (COPD). Breath actuated (BA) technology offers more consistent dose delivery5 and the reduction of fugitive emissions6 into the care environment. This in vitro study was undertaken to determine delivery of tobramycin using a BA nebulizer/compressor system and two breath enhanced (BE) nebulizer/compressor systems.
Evaluation of Several Small Volume Nebulizer (SVN) Kits Intended for Aerosol Treatments in the Home
Nebulizer therapy is common in the home, but different compressor nebulizer combinations may alter the desired therapeutic effects. Many of the home-based kits provided to patients offer a mix of reusable and disposable devices with significantly different aerosol performance. This poster summarizes in vitro data for 6 kits with results that may affect patient outcomes.
A Risk Evaluation for Fugitive Aerosol Emissions When Using Different Nebulizer Systems: Potential Mechanisms, Impact of Device Type and Mitigation Strategies
This poster provides a review of different nebulizer designs, highlighting the potential for the loss of medicinal and bio-aerosols in their use scenarios. It provides mitigation strategies to greatly reduce or virtually eliminate the potential risks of fugitive emissions associated with nebulized drug delivery.
AEROECLIPSE® II BAN™ Nebulizer
Let Breathing Take Control
The AEROECLIPSE® II BAN™ Nebulizer produces aerosol with a high respirable dose and optimal particle size ONLY when the patient is inhaling. Reducing medication waste and the aerosol particulate that ends up in the room by 3-4 times than that of a continuously run jet nebulizer.3,4 This helps minimize exposure to environmental loss for front line healthcare professionals.
Click image for
Larger View
Clinical Evidence
Not all jet nebulizers are created equal. For dose assurance and a safe environment for your frontline staff, choose AEROECLIPSE® II BAN™ Nebulizer.
Continuous output nebulizers risk the potential under-dosing as disease progresses or if a patient pauses during treatment. Clinicians should be aware of the differences between nebulizers and their impact on dose delivery. Watch the video.
Significantly more aerosol is delivered to the therapeutically important areas of the lungs when compared to a continuously running nebulizer. Learn more.
Implementation of the AEROECLIPSE® II BAN™ Nebulizer in a hospital Emergency Department resulted in an 88% reduction in the cost of sick days by reducing the number of sick days by 60%. Learn more.
When different inspiratory:expiratory ratios were considered, there was significant variance in the Delivered Dose and the Respirable Dose between different brands of non-breath-activated nebulizer. Consideration should be given to revision of the test protocols included in the guidelines, to reflect more accurately the potential therapeutic dose that is delivered to a realistic spectrum of breathing patterns. Learn more.
This Study Summary is designed to identify how the AEROECLIPSE® II BAN™ Nebulizer has performed in both in vitro and in vivo studies with various formulations and versus other nebulizers. Learn more.
AEROCHAMBER PLUS®
FLOW-VU®
For respiratory patients, getting the most from life means getting the most from their inhaler medication.
Clinical Evidence
A quick view of the most recent peer-reviewed evidence supporting the chambers. Learn more.
Only AEROCHAMBER PLUS® FLOW-VU® chambers were equivalent to the reference device data listed in virtually all innovator inhalers currently approved in the US and European markets. Differences in chamber design, materials and function mean that chambers should not be automatically considered interchangeable. Learn more.
The author found that it was unequivocal that differences exist between different chambers which in a number of cases are sufficiently large that meaningful and overt clinical differences would be anticipated as a result. Learn more.
Some “antistatic” valved holding chambers (aVHC) have poor antistatic properties and should therefore be considered non-antistatic and primed. Differences in antistatic properties are an important cause of the large performance differences between aVHCs. Learn more.
For a copy of our full Clinical Study Summary, please contact your Territory Manager.
AEROBIKA® OPEP Device
Oscillating Positive Expiratory Pressure or OPEP therapy helps stent open and clear blocked airways. On exhalation the device creates a unique oscillation and pressure dynamic to address the structural and functional challenges in the airways. The combination of oscillations and pressure opens the airways and aids in moving mucus into the central airways, where it can be coughed out. The device is drug-free so there are no side effects or drug interactions and it is easy-to-use, so patients are able to transition home with the device.
Click for larger view of unblocked lungs (teal areas) 2 after 3 weeks of using the Aerobika® OPEP device.
Clinical Resources
An evidence assessment for the integration of the AEROBIKA® OPEP device into the care pathway for COVID-19 patients with airway clearance needs. Watch the video.
- 28% decrease in readmissions for COPD exacerbations. Learn more.
- 39% decrease in all-cause rehospitalizations and lower costs for post-operative recovery. Learn more.
Contact your Territory Manager today for a copy of our full Clinical Study Summary for the AEROBIKA® OPEP device.
